AMGNCongressional Stock Trades
Amgen Inc
Biological Products, (No Diagnostic Substances)
Congressional stock trades in Amgen Inc (AMGN) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
36
Politicians Trading
13
Last Traded
Aug 26, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Ro KhannaD | Aug 7, 2026 | Jul 8, 2026 | Buy | $1,001 - $15,000 | +4.80% |
| Ro KhannaD | Jul 6, 2026 | Jun 30, 2026 | Buy | $1,001 - $15,000 | +6.50% |
| Ro KhannaD | Jul 6, 2026 | Jun 16, 2026 | Buy | $1,001 - $15,000 | +10.87% |
| Ro KhannaD | Jul 6, 2026 | Jun 2, 2026 | Buy | $1,001 - $15,000 | +17.48% |
| David TaylorR | Jun 12, 2026 | Jun 5, 2026 | Buy | $1,001 - $15,000 | +10.32% |
| Ro KhannaD | Jun 9, 2026 | May 27, 2026 | Buy | $15,001 - $50,000 | +14.76% |
| Ro KhannaD | Jun 9, 2026 | May 1, 2026 | Buy | $15,001 - $50,000 | +16.93% |
| David TaylorR | Feb 2, 2026 | Jan 16, 2026 | Buy | $1,001 - $15,000 | +16.72% |
| Marjorie Taylor GreeneR | Oct 28, 2025 | Oct 24, 2025 | Buy | $1,001 - $15,000 | +32.18% |
| Marjorie Taylor GreeneR | Sep 27, 2025 | Sep 11, 2025 | Buy | $1,001 - $15,000 | +36.40% |
| Lisa C. McClainR | Aug 13, 2025 | Jun 24, 2025 | Buy | $1,001 - $15,000 | +38.98% |
| Cliff BentzR | Jul 9, 2025 | Jun 6, 2025 | Buy | $1,001 - $15,000 | +32.83% |
| Marjorie Taylor GreeneR | May 19, 2025 | May 14, 2025 | Buy | $1,001 - $15,000 | +47.04% |
| Jared MoskowitzD | May 9, 2025 | Apr 16, 2025 | Buy | $1,001 - $15,000 | +36.45% |
| Jared MoskowitzD | May 9, 2025 | Apr 16, 2025 | Buy | $1,001 - $15,000 | +36.45% |
| Jefferson ShreveR | May 8, 2025 | Apr 11, 2025 | Buy | $15,001 - $50,000 | +34.85% |
| Marjorie Taylor GreeneR | May 6, 2025 | May 5, 2025 | Buy | $1,001 - $15,000 | +37.70% |
| Jefferson ShreveR | Mar 9, 2025 | Feb 24, 2025 | Buy | $15,001 - $50,000 | +24.52% |
Price History
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.